Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials.

ABSTRACT:

Importance

Because cancer drugs given in combination have the potential for increased tumor-cell killing, finding the best combination partners for programmed cell death 1 (PD-1) checkpoint inhibitors could improve clinical outcomes for patients with cancer.

Objective

To identify optimal strategies for combining PD-1 immune checkpoint inhibitors with other cancer therapies.

Design, setting, and participants

This cross-sectional study compiled 319 results from 98 clinical trials testing PD-1 pathway inhibitors alone or in combination with other agents among 24 915 patients with metastatic cancer. All clinical trials had a primary completion date before September 16, 2018. Data analysis was conducted from November 2018 to August 2019.

Exposures

Patients with meta

SUBMITTER: Schmidt EV 

PROVIDER: S-EPMC12549068 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature